SCHEMBL3017983

SCHEMBL3017983

Cc1ccccc1-c1csc(N2CCN(S(=O)(=O)c3ccc(F)c(Cl)c3)CC2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.53
ALDH1A1 P00352 4/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
MAPT P10636 4/20 0.51
HSD17B10 Q99714 2/20 0.51
USP2 O75604 1/20 0.51
RECQL P46063 1/20 0.51
LMNA P02545 6/20 0.50
TSHR P16473 4/20 0.50
MAPK1 P28482 4/20 0.50
HTT P42858 4/20 0.50
KMT2A Q03164 6/20 0.48
MEN1 O00255 5/20 0.48
POLB P06746 2/20 0.48
GAA P10253 1/20 0.48
NPSR1 Q6W5P4 1/20 0.45
AR P10275 1/20 0.45
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
LPAR1 Q92633 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015947 0.93 ALDH1A1 (0.52) SMN1; SMN2ALDH1A1L3MBTL1MAPTHSD17B10
SCHEMBL3017471 0.91 SMN1; SMN2 (0.52) SMN1; SMN2ALDH1A1L3MBTL1MAPTHSD17B10
SCHEMBL3011119 0.90 AR (0.55) SMN1; SMN2ALDH1A1L3MBTL1MAPTHSD17B10
SCHEMBL3015549 0.89 ALDH1A1 (0.54) SMN1; SMN2ALDH1A1L3MBTL1MAPTHSD17B10
SCHEMBL3017725 0.89 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1L3MBTL1MAPTHSD17B10
SCHEMBL3019049 0.88 MAPT (0.48) SMN1; SMN2ALDH1A1L3MBTL1MAPTHSD17B10
SCHEMBL3017595 0.88 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1L3MBTL1MAPTHSD17B10
SCHEMBL3008110 0.88 MAPT (0.57) SMN1; SMN2ALDH1A1L3MBTL1MAPTHSD17B10
SCHEMBL3006385 0.87 ALDH1A1 (0.71) SMN1; SMN2ALDH1A1L3MBTL1MAPTHSD17B10
SCHEMBL3019761 0.86 ALDH1A1 (0.55) SMN1; SMN2ALDH1A1L3MBTL1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.